我們已在上線!
進一步了解
SURF
Surface Oncology, Inc. Common Stock
SURF
SURF
已下市
SURF已於2023年9月7日下市。
關於: Surface Oncology Inc is a clinical-stage immuno-oncology company. It is developing new therapies that modify the spaces in and around tumors in the tumor microenvironment to create conditions that support and sustain anti-tumor immune responses. The company's pipeline products are SRF231, SRF373, SRF617, and SRF388. Geographically, the activities are carried out throughout the region of the United States.
員工: 35
新聞
正面
中性
負面
市場情緒
3個月
正面
0%
中性
0%
負面
0%
我們尚未收到任何關於SURF的最新新聞文章。
價格圖表採用Lightweight Charts™實作